Academic literature on the topic 'Hu antibodies'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hu antibodies.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Hu antibodies"
Monstad, S. E., L. Drivsholm, A. Storstein, J. H. Aarseth, M. Haugen, B. Lang, A. Vincent, and C. A. Vedeler. "Hu and Voltage-Gated Calcium Channel (VGCC) Antibodies Related to the Prognosis of Small-Cell Lung Cancer." Journal of Clinical Oncology 22, no. 5 (March 1, 2004): 795–800. http://dx.doi.org/10.1200/jco.2004.01.028.
Full textVerschuuren, J., A. Twijnstra, M. De Baets, F. Thunnissen, J. Dalmau, and P. van Breda Vriesman. "Hu antigens and anti-Hu antibodies in a patient with myxoid chondrosarcoma." Neurology 44, no. 8 (August 1, 1994): 1551. http://dx.doi.org/10.1212/wnl.44.8.1551.
Full textManley, Geoffrey T., Peter Sillevis Smitt, Josep Dalmau, and Jerome B. Posner. "Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites." Annals of Neurology 38, no. 1 (July 1995): 102–10. http://dx.doi.org/10.1002/ana.410380117.
Full textTOTLAND, C., J. AARSETH, and C. VEDELER. "Hu and Yo antibodies have heterogeneous avidity." Journal of Neuroimmunology 185, no. 1-2 (April 2007): 162–67. http://dx.doi.org/10.1016/j.jneuroim.2007.01.016.
Full textGreenlee, John E., John D. Steffens, Susan A. Clawson, Kenneth Hill, and Josep Dalmau. "Anti-Hu antibodies in Merkel cell carcinoma." Annals of Neurology 52, no. 1 (June 21, 2002): 111–15. http://dx.doi.org/10.1002/ana.10225.
Full textFarina, Antonio, Macarena Villagrán-García, Nicolás Lundahl Ciano-Petersen, Alberto Vogrig, Sergio Muñiz-Castrillo, Luc Taillandier, Maud Michaud, et al. "Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors." Neurology - Neuroimmunology Neuroinflammation 10, no. 1 (November 29, 2022): e200058. http://dx.doi.org/10.1212/nxi.0000000000200058.
Full textZiller, MG, EL Göttke, M. Bambonye, and R. Dalfen. "P.039 New association of anti-Hu positive limbic encephalitis and sensory ganglionopathy with small cell gastric tumour." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 43, S2 (June 2016): S30. http://dx.doi.org/10.1017/cjn.2016.143.
Full textWilliams, S. S., T. Umemoto, H. Kida, E. A. Repasky, and R. B. Bankert. "Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies." Journal of Immunology 149, no. 8 (October 15, 1992): 2830–36. http://dx.doi.org/10.4049/jimmunol.149.8.2830.
Full textMukherjee, Jean, Kerry Chios, Dianne Fishwild, Deborah Hudson, Susan O'Donnell, Stephen M. Rich, Arthur Donohue-Rolfe, and Saul Tzipori. "Production and Characterization of Protective Human Antibodies against Shiga Toxin 1." Infection and Immunity 70, no. 10 (October 2002): 5896–99. http://dx.doi.org/10.1128/iai.70.10.5896-5899.2002.
Full textCamdessanché, Jean‐Philippe, Jean‐Christophe Antoine, Jérôme Honnorat, Christophe Vial, Philippe Petiot, Philippe Convers, and Daniel Michel. "Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies." Brain 125, no. 1 (January 1, 2002): 166–75. http://dx.doi.org/10.1093/brain/awf006.
Full textDissertations / Theses on the topic "Hu antibodies"
Villagrán-García, Macarena. "Clinical-immunological characterization and immune tolerance breakdown in paraneoplastic neurological syndromes associated with Hu antibodies." Electronic Thesis or Diss., Lyon 1, 2024. http://www.theses.fr/2024LYO10259.
Full textHu antibodies, the most common in paraneoplastic neurological syndromes (PNS), strongly indicate small-cell lung cancer (SCLC). The clinical spectrum of Hu-PNS is diverse, most patients develop multifocal central, peripheral, and/or autonomic nervous system dysfunction. Despite extensive research, questions remain, namely regarding the immunological basis of clinical heterogeneity and why only a minority of SCLC patients develop Hu-PNS. Our PhD project aims to phenotype Hu-PNS patients, explore the immunogenetics and humoral responses underlying neurological phenotypes, and the genomic and transcriptomic features of their SCLC. First, we described 466 Hu-PNS patients. Hierarchical clustering identified three groups: patients with central nervous system (CNS) involvement; isolated neuropathy; and mixed CNS/peripheral phenotypes. Overall survival was similar across groups, primarily determined by cancer, but dysautonomia, present in 26% of patients, significantly influenced neurological mortality. Prominent CNS dysfunction led to fatal cardiovascular dysautonomia or central hypoventilation, while peripheral involvement was associated with gastrointestinal or secretomotor alterations, without increased mortality risk. We also characterized patients who developed neurological syndromes with Hu antibodies after immune checkpoint inhibitor (ICI) treatment. These patients were clinically indistinguishable from spontaneous cases and shared a strong association with SCLC, suggesting ICIs may induce Hu-PNS. Second, we immunologically investigated neurological phenotypes using two approaches. HLA genotyping of 100 patients confirmed an association with the DR3~DQ2 haplotype, particularly in patients with sensory neuropathy, and absent in those with only CNS involvement. Phage immunoprecipitation sequencing was used to evaluate Hu antibody epitope reactivity and other autoantibodies in serum and/or CSF of 210 patients. We found no direct clinical association with the Hu dominant epitope, but epitope reactivity differed between serum and CSF in 75% of patients with paired samples. This variation correlated with sample timing and phenotype: CSF from patients with differing serum/CSF epitopes was collected later after PNS onset, while patients with serum/CSF consistent epitope reactivity always had CNS phenotypes. In addition, we identified reactivities to other proteins, some more specific to serum or CSF, and a subset linked to specific phenotypes. Third, we examined SCLC molecular features of Hu-, GABAbR-PNS and control patients. Next-generation sequencing, copy number variation analysis, and bulk-RNA sequencing revealed no mutations, gains, deletions, or overexpression in the Hu gene family of Hu-PNS SCLC. However, a distinct transcriptomic profile with upregulated genes largely related to immune system processes characterized these tumors. We also identified specific genes upregulated in the SCLC of patients with sensory neuropathy, some of which were linked to axonogenesis and neuropathy development. Our findings suggest multiple factors contribute to Hu-PNS clinical variability, particularly a broad range of additional autoantigens. These may be partly driven by gene expression patterns in SCLC, as some upregulated genes in patients with sensory neuropathy were linked to axonogenesis. Genetic predisposition may also favor specific phenotypes, as the DR3~DQ2 haplotype was associated with sensory neuropathy. Compartmentalization within the nervous system could further contribute, as most patients targeted different Hu epitopes in serum and CSF, and some autoantigens were more specific to CSF. Finally, Hu genes alterations in SCLC are unlikely causes of neoantigenicity, while a distinct immune-related gene profile and ICIs could contribute to immune tolerance breakdown. This work advances understanding of Hu-PNS complexity and paves the way for further studies into the immunological and molecular drivers of paraneoplastic immunity
Books on the topic "Hu antibodies"
McKeon, Andrew. Autoimmune Encephalitis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0097.
Full textHodgkiss, Andrew. Psychiatric consequences of particular cancers. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0004.
Full textBook chapters on the topic "Hu antibodies"
Miller, Aaron E., Tracy M. DeAngelis, Michelle Fabian, and Ilana Katz Sand. "On the Right Tract." In Neuroimmunology, 109–12. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190693190.003.0020.
Full textConference papers on the topic "Hu antibodies"
Yagnik, Deepti, Josephine Chan, Ben McGettigan, Andrew Laycock, and Allycia MacDonald. "3121 New onset refractory epilepsy (NORSE) secondary to anti-glutamic acid decarboxylase (anti-GAD) and anti-Hu antibodies related paraneoplastic encephalitis from lymphocyte-rich thymoma." In ANZAN Annual Scientific Meeting 2024 Abstracts, A39.3—A40. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/bmjno-2024-anzan.110.
Full textLi, Xi, Kara L. Maki, and Michael J. Schertzer. "A Low Cost Fabrication Method for Electrowetting Assisted Desiccation of Colloidal Droplets." In ASME 2017 Fluids Engineering Division Summer Meeting. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/fedsm2017-69465.
Full text